DOI:
10.1039/C5RA00796H
(Paper)
RSC Adv., 2015,
5, 24327-24335
An efficient catalyst-free chemoselective multicomponent reaction for the synthesis of pyrimidine functionalized pyrrolo-annelated derivatives†
Received
14th January 2015
, Accepted 25th February 2015
First published on 25th February 2015
Abstract
An efficient method for the synthesis of pyrimidine functionalized pyrrolo-annelated derivatives has been developed via a catalyst-free, one-pot chemoselective multicomponent domino reaction. The method offers ease of execution, easy and column free separation, mild reaction conditions, and high yields.
Introduction
Multicomponent reactions (MCRs) are alternative green techniques to multistep processes. Application of MCRs in the synthesis of natural products and building blocks are well documented in the literature.1 MCRs have remarkable impact in the field of medicinal chemistry, combinatorial synthesis, and pharmaceutical industry due to their loftier gains like simplistic execution, convergence, less energy consumption, more productivity with excellent chemo and regio-selectivities.2 Therefore, the design of new chemo- and regio-selective multicomponent reactions for easy and efficient synthesis is an ongoing challenge to synthetic chemists.3 In recent literature the number of reports regarding reagent and substrate based multicomponent reactions are quite high.4 Especially isocyanide based multicomponent reactions (IMCRs)5 and arylglyoxal based multicomponent reactions6 are well established for the construction of diverse molecular libraries in easy and efficient way.
Moreover, pyrrole core unit is present in many natural products, its analogues are renowned in medicine7 and many reports were published in recent literature8 to produce their novel analogues of indoles,9 carbazoles,10 pyrrolo pyrimidines,11 indeno pyrroles,12 and pyrrolo naphthoquinones.13 Pyrimidinylpyrrole motif appears in several natural and bioactive products like meridianins, variolins, psammopemmins, hyrtinadine, aplicyanins etc.14 and therefore, cyclic systems with this structural motif draw considerable attention in the field of combinatorial chemistry and drug discovery.15 In continuation to our studies towards the synthesis of pyrimidine heterocycles and drug intermediates via multicomponent reactions,16 herein we report an efficient chemoselective multicomponent one-pot strategy for the construction of novel pyrimidinylpyrrole fused cyclic systems under catalyst-free conditions using different cyclic 1,3-dicarbonyl compounds (Scheme 1).
 |
| Scheme 1 Synthesis of pyrimidine functionalized pyrrolo-annelated derivatives. | |
Results and discussion
We initiated our study by performing a one-pot reaction of 1,3-indanedione 1, 4-methoxy aniline 2a, 1,3-dimethyl barbituric acid 3a, and 4-methyl phenylglyoxal hydrate 4a in equimolar quantities using different solvents. It was found that ethanolic mixture of all the reactants under reflux conditions gave 5a in 89% yield. Other solvents like water (24%), toluene (39%), acetonitrile (59%), dimethylformamide (56%), chloroform (42%), acetic acid (64%), and methanol (79%) are comparatively less effective towards this transformation. Moreover, it is remarkable to note here that the reaction occurred at room temperature also but with a lesser yield (10%). A variation in temperature revealed that reflux condition is the best reaction condition for synthesis of the desired product. It was observed that the product 5-(1-(4-methoxyphenyl)-4-oxo-2-(p-tolyl)-1,4-dihydroindeno[1,2-b]pyrrol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione 5a was formed exclusively without the formation of the other likely products 5(i) or 5(ii) (Scheme 2). The 1H-NMR spectrum of 5a showed a singlet with 6 protons at 3.38 ppm. The N-methyl signal at 28.81 ppm in 13C-NMR clearly shows that methyl protons of barbituric acid are at the same chemical environment which indicates the formation of 5a. The chemoselective formation of enamine of 1,3-diketones 1 and 3a with aromatic amine 2a can explain the formation of 5a rather than 5(i) or 5(ii). Due to resonance of the amide nitrogen towards the carbonyl group, the reactivity of barbituric acid amide ketone is less than the ketone group of 1 to form the enamine intermediate with aromatic amine 2a, which lead to selective formation of 5a but not 5(i) or 5(ii).
 |
| Scheme 2 Chemoselective formation of pyrrolo-annelated derivative 5a. | |
The scope of the reaction was examined under optimized reaction conditions, with different substituted aromatic amines 2 and aromatic phenylglyoxal hydrates 4. The results obtained are summarized in Table 1. Generalization study reveals that the method is suitable with a wide variety of substituted aromatic amines and arylglyoxal hydrates with excellent yields (Table 1, entries 5a–k). The reaction was also equally effective with aromatic amines and phenylglyoxal hydrates containing both the electron-withdrawing and -donating groups. The products thus obtained were characterized by spectroscopic analyses.
Table 1 Chemoselective synthesis of 3-(pyrimidin-5-yl)indeno[1,2-b]pyrrol-4(1H)-one derivatives 5a–ka

|
Reaction conditions: indane-1,3-dione 1 (1 mmol), aromatic amine 2 (1 mmol), barbituric acid 3a (1 mmol) and phenylglyoxal hydrate 4 (1 mmol) was refluxed in 8 mL of ethanol for 30 min. |
 |
Encouraged by the above results, we extended our study to find the feasibility of the method with other cyclic 1,3-dicarbonyl compounds viz. dimedone 6 and 2-hydroxy naphthoquinone 8 (Scheme 3). We found that under identical reaction condition the desired pyrimidinylpyrrole fused derivatives 7 and 9 were obtained in good yields without the formation of any other products. The generalization study for the formation of 7 is listed in Table 2. The scope of the reaction scheme was well tolerated with various substituted aromatic amines 2, barbituric acid 3 and arylglyoxal hydrate 4 and successfully furnished the corresponding pyrimidinylpyrrole fused analogues of 7a–l in good to excellent yields. Furthermore, we observed that the free NH group of 3b did not interrupt the reaction process, constructing the desired pyrimidinylpyrrole fused derivative in good yields (Scheme 3).
 |
| Scheme 3 Chemoselective formation of pyrrolo-annelated derivatives 7 & 9. | |
Table 2 Synthesis of 3-(pyrimidin-5-yl)-6,7-dihydro-1H-indol-4(5H)-one derivatives 7a–la

|
Reaction conditions: dimedone 6 (1 mmol), aromatic amine 2 (1 mmol), barbituric acid 3 (1 mmol) and arylglyoxal hydrate 4 (1 mmol) was refluxed in 8 mL of ethanol for 30 min. |
 |
We then performed the same reaction using 6-amino-1,3-dimethyluracil as enamine instead of in situ generated enamine of an aromatic amine and cyclic 1,3-dicarbonyl compound which generates enamine and we observed the formation of pyrimidinylpyrrole fused pyrimidine derivative in good yields. In a typical case, a mixture of 1,3-dimethyl-6-amino uracil 10a, 1,3-dimethyl barbituric acid 3a, and phenylglyoxal hydrate 4 in ethanol was refluxed with stirring for 30 min (monitored vide TLC). On completion, after usual work-up the desired pyrimidinylpyrrole fused pyrimidine derivative 11a was obtained in 88% yield. The reaction was then generalized by using different 6-amino uracil 10a–c, barbituric acid 3a–b, and arylglyoxal hydrates 4 to obtain the substrate scope of the reaction scheme (Table 3). The nature of substituent's in the substrates played no significant role towards the formation of the products and in all the cases reaction proceeds smoothly to give 11 as the product exclusively.
Table 3 Substrate scope for the synthesis of 3-(pyrimidin-5-yl)indeno[1,2-b]pyrrol-4(1H)-one derivatives 11a–ja

|
Reaction conditions: 6-aminouracil 10 (1 mmol), barbituric acid 3a (1 mmol) and phenylglyoxal hydrate 4 (1 mmol) was refluxed in 8 mL of ethanol for 30 min. |
 |
Although the detailed mechanistic studies are not performed, a possible mechanism for the formation of pyrimidinylpyrrolo fused cyclic compounds is shown in Scheme 4. It is assumed that under reflux conditions 3 and 4 form Knoevenagel product A, which undergoes 1,3-dipolar cyclization with 6-amino uracil 10, leads to the formation of 11. Similarly, 1,3-dipolar cyclization of A with in situ generated enaminones B from cyclic 1,3-dicarbonyl compounds and aromatic amines forms other pyrrole fused ring systems 5 or 7 or 9.
 |
| Scheme 4 Plausible mechanism for the formation of pyrrolo-annelated derivatives. | |
To support our mechanistic postulate, we have carried out the reaction in three-component as well as two-component manner. In three component process, the reaction of 1,3-dimethylbarbituric acid 3a, phenylglyoxal hydrate 4a with enamine 12 (prepared from aromatic amine 2a and dimedone 6)17 under reflux conditions in ethanol was performed and got the desired product 7e. Moreover, the two component reaction of enamine 12 and Knoevenagel product 13 also resulted the product 7e under similar reaction conditions. Compound 13 was prepared from 3a and 4a by using procedure reported in the earlier literature.18 These experiments supports our assumption that the reaction was proceeded through in situ formation of an enamine and Knoevenagel products (Scheme 5).
 |
| Scheme 5 Mechanistic studies for the formation of 7e. | |
Conclusions
In conclusion, we have developed a facile and efficient one-pot ecofriendly multicomponent reaction strategy for the construction of pyrimidinyl functionalized pyrrole fused heterocycles. A variety of arylglyoxal hydrates have been shown to participate in a clean reaction with barbituric acid and enaminones or in situ generated enaminones from cyclic 1,3-dicarbonyl compounds and several aromatic amines under catalyst-free conditions. The methodology provides a rapid access to pyrimidinyl functionalized pyrrolo-annelated derivatives with excellent yields without tedious workup and purification processes. Further, we believe that our developed methodology will be a good alternative for the synthesis of pyrrole fused heterocycles.
Experimental
General experimental methods
Phenylglyoxal hydrates were prepared accordingly earlier reported procedure,19 remaining all the other commercially available reagents were used as received. IR Spectra were recorded on a SHIMADZU FTIR-8400 instrument. NMR spectra were recorded on Avance DPX 300 MHz FT-NMR spectrometer and Avance DPX 500 MHz FT-NMR using tetramethyl silane (TMS) as an internal standard. Mass spectra were recorded on ESQUIRE 3000 Mass spectrometer. All the experiments were monitored by thin layer chromatography (TLC). TLC was performed on pre-coated silica gel plates (Merck).
Typical procedure for the synthesis of pyrrolo-annelated derivatives (5 or 7 or 9)
1,3-Indanedione 1 (1 mmol), aromatic amine 2 (1 mmol), barbituric acid 3 (1 mmol), arylglyoxal hydrate 4 (1 mmol), and ethanol (8 mL) were taken in a 50 mL round bottom flask. The mixture was stirred at refluxing temperature for 30 min. After completion of the reaction, the reaction mixture was cooled, formed solids were filtered and washed with cold ethanol to obtain the products 5a–k.
Similarly, the reaction was carried out by taking dimedone 6 or 2-hydroxy-1,4-naphthoquinone 8 in place of indane-1,3-dione 1 to obtain 7 or 9.
5-(1-(4-Methoxyphenyl)-4-oxo-2-(p-tolyl)-1,4-dihydroindeno[1,2-b]pyrrol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5a). Black solid (yield 89%); mp: 275.6–276.4 °C; IR (KBr, ν/cm−1): 3431, 3052, 2966, 2845, 1693, 1633, 1605, 1519, 1446, 1374, 1287, 1253, 1118, 1029, 899, 868, 841, 828, 769, 751, 726, 654; 1H NMR (300 MHz, CDCl3): δ (ppm), 7.28 (d, J = 7.2 Hz, 3H), 7.17 (d, J = 8.8 Hz, 2H), 7.09 (d, J = 7.9 Hz, 2H), 7.00 (dd, J = 5.2, 3.1 Hz, 2H), 6.88 (d, J = 8.9 Hz, 2H), 6.36 (dd, J = 5.2, 2.9 Hz, 1H), 4.52 (s, 1H), 3.83 (s, 3H), 3.38 (s, 6H), 2.31 (s, 3H); 13C NMR (75 MHz, CDCl3): 186.09, 167.37, 159.54, 151.68, 151.37, 141.46, 139.08, 138.47, 135.82, 132.49, 130.56, 129.65, 129.25, 128.25, 128.14, 125.87, 123.46, 120.34, 117.48, 114.39, 112.47, 55.49, 46.59, 28.81, 21.32; MS (GCMS, m/z) 519.9 [M]+; anal. calcd for C31H25N3O5: C, 71.67; H, 4.85; N, 8.09; O, 15.39. Found C, 71.64; H, 4.86; N, 8.08; O, 15.42.
5-(1-(4-Methoxyphenyl)-4-oxo-2-phenyl-1,4-dihydroindeno[1,2-b]pyrrol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5b). Black solid (yield 74%); mp: 295.0–295.8 °C; IR (KBr, ν/cm−1): 3423, 3062, 2997, 2956, 2932, 2840, 1752, 1683, 1607, 1516, 1445, 1376, 1291, 1246, 1119, 1023, 987, 898, 886, 785, 757, 725, 708, 686; 1H NMR (300 MHz, CDCl3): δ (ppm), 7.45–7.35 (m, 2H), 7.30 (dd, J = 7.5, 5.0 Hz, 4H), 7.17 (d, J = 8.8 Hz, 2H), 7.01 (dd, J = 5.1, 3.1 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 6.43–6.33 (m, 1H), 4.53 (s, 1H), 3.83 (s, 3H), 3.39 (s, 6H); 13C NMR (75 MHz, CDCl3): 186.06, 167.32, 159.59, 151.65, 151.49, 141.28, 139.06, 135.75, 132.54, 130.71, 129.55, 128.86, 128.53, 128.23, 123.50, 120.39, 117.56, 114.42, 112.65, 55.49, 46.55, 28.82; MS (GCMS, m/z) 505.9 [M]+; anal. calcd for C30H23N3O5: C, 71.28; H, 4.59; N, 8.31; O, 15.82. Found C, 71.26; H, 4.58; N, 8.33; O, 15.83.
5-(2-(4-Bromophenyl)-1-(4-methoxyphenyl)-4-oxo-1,4-dihydroindeno[1,2-b]pyrrol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5c). Red solid (yield 81%); mp: 299.8–300.6 °C; IR (KBr, ν/cm−1): 3420, 3075, 2966, 2908, 2833, 1692, 1605, 1519, 1448, 1375, 1286, 1254, 1185, 1117, 1089, 1030, 983, 898, 868, 834, 812, 768, 753, 725, 654; 1H NMR (300 MHz, CDCl3): δ (ppm), 7.43 (d, J = 8.4 Hz, 2H), 7.33–7.27 (m, 3H), 7.16 (d, J = 8.8 Hz, 2H), 7.02 (dd, J = 4.8, 3.5 Hz, 2H), 6.91 (d, J = 8.8 Hz, 2H), 6.38 (dd, J = 5.4, 2.7 Hz, 1H), 4.46 (s, 1H), 3.85 (s, 3H), 3.39 (s, 6H); 13C NMR (75 MHz, CDCl3): 185.93, 167.18, 159.75, 151.73, 151.58, 139.93, 138.96, 135.54, 132.62, 132.19, 131.81, 129.24, 128.39, 128.21, 127.82, 123.62, 123.07, 120.37, 117.66, 114.61, 112.98, 55.54, 46.50, 28.86; MS (GCMS, m/z) 584.8 [M]+; anal. calcd for C30H22BrN3O5: C, 61.66; H, 3.79; Br, 13.67; N, 7.19; O, 13.69. Found C, 61.64; H, 3.80; Br, 13.66; N, 7.18; O, 13.72.
5-(2-(4-Chlorophenyl)-1-(4-methoxyphenyl)-4-oxo-1,4-dihydroindeno[1,2-b]pyrrol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5d). Red solid (yield 82%); mp: 279.8–280.6 °C; IR (KBr, ν/cm−1): 3436, 2948, 2929, 1695, 1681, 1601, 1517, 1420, 1376, 1286, 1260, 1093, 1018, 840, 767, 726; 1H NMR (300 MHz, CDCl3): δ (ppm), 7.38–7.25 (m, 5H), 7.16 (d, J = 8.8 Hz, 2H), 7.02 (dd, J = 5.0, 3.3 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 6.38 (dd, J = 5.5, 2.7 Hz, 1H), 4.46 (s, 1H), 3.85 (s, 3H), 3.39 (s, 6H); 13C NMR (75 MHz, CDCl3): 185.94, 167.20, 159.74, 151.70, 151.58, 139.93, 138.97, 135.56, 134.75, 132.61, 131.96, 129.26, 128.86, 128.38, 128.21, 127.35, 123.61, 120.35, 117.65, 114.59, 113.00, 55.53, 46.50, 28.85; MS (GCMS, m/z) 539.9 [M]+; anal. calcd for C30H22ClN3O5: C, 66.73; H, 4.11; Cl, 6.57; N, 7.78; O, 14.81. Found C, 66.74; H, 4.12; Cl, 6.56; N, 7.76; O, 14.82.
5-(2-(4-Methoxyphenyl)-4-oxo-1-(p-tolyl)-1,4-dihydroindeno[1,2-b]pyrrol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5e). Red solid (yield 81%); mp: 298.6–299.4 °C; IR (KBr, ν/cm−1): 3435, 3075, 2966, 2833, 1694, 1678, 1606, 1516, 1453, 1376, 1291, 1257, 1178, 1114, 1032, 985, 898, 844, 800, 768, 727; 1H NMR (300 MHz, CDCl3): δ (ppm), 7.31 (t, J = 7.9 Hz, 3H), 7.15 (dd, J = 18.9, 8.3 Hz, 4H), 6.99 (dt, J = 7.8, 3.9 Hz, 2H), 6.81 (d, J = 8.7 Hz, 2H), 6.37 (dd, J = 5.2, 3.0 Hz, 1H), 4.50 (s, 1H), 3.77 (s, 3H), 3.38 (s, 6H), 2.38 (s, 3H); 13C NMR (75 MHz, CDCl3): 186.10, 167.41, 159.71, 151.68, 151.06, 141.13, 139.04, 138.81, 135.86, 134.33, 132.47, 132.11, 129.91, 128.10, 126.86, 123.43, 121.13, 120.39, 117.52, 113.94, 112.51, 55.22, 46.60, 28.81, 21.22; MS (GCMS, m/z) 519.9 [M]+; anal calcd for C31H25N3O5: C, 71.67; H, 4.85; N, 8.09; O, 15.39. Found C, 71.64; H, 4.86; N, 8.09; O, 15.41.
1,3-Dimethyl-5-(4-oxo-1,2-di-p-tolyl-1,4-dihydroindeno[1,2-b]pyrrol-3-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (5f). Black solid (yield 70%); mp: 189.2–190.0 °C; IR (KBr, ν/cm−1): 3428, 3023, 2960, 2925, 1694, 1679, 1633, 1603, 1516, 1495, 1453, 1417, 1373, 1286, 1261, 1187, 1117, 1088, 1022, 982, 898, 867, 837, 826, 767, 753, 727, 655; 1H NMR (300 MHz, CDCl3): δ (ppm), 7.30–7.24 (m, 3H), 7.13 (dt, J = 10.9, 8.1 Hz, 6H), 6.99 (dd, J = 4.9, 3.2 Hz, 2H), 6.37 (dd, J = 4.9, 3.3 Hz, 1H), 4.52 (s, 1H), 3.38 (s, 6H), 2.38 (s, 3H), 2.31 (s, 3H); 13C NMR (75 MHz, CDCl3): 186.12, 167.37, 151.69, 151.19, 141.31, 139.06, 138.82, 138.47, 135.84, 134.33, 132.49, 130.53, 129.90, 129.24, 128.13, 126.84, 125.89, 123.45, 120.50, 117.57, 112.57, 46.56, 28.81, 21.34, 21.23; MS (GCMS, m/z) 504.1 [M]+; anal. calcd for C31H25N3O4: C, 73.94; H, 5.00; N, 8.34; O, 12.72. Found C, 73.94; H, 5.01; N, 8.33; O, 12.72.
5-(2-(4-Chlorophenyl)-4-oxo-1-(p-tolyl)-1,4-dihydroindeno[1,2-b]pyrrol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5g). Red solid (yield 68%); mp: 300.4–301.2 °C; IR (KBr, ν/cm−1): 3432, 3057, 2961, 2916, 1695, 1678, 1604, 1505, 1458, 1377, 1288, 1117, 1087, 1015, 899, 844, 829, 766, 753, 728, 659; 1H NMR (300 MHz, CDCl3): δ (ppm), 7.39–7.28 (m, 3H), 7.27 (d, J = 3.6 Hz, 2H), 7.20 (d, J = 8.2 Hz, 2H), 7.11 (d, J = 8.2 Hz, 2H), 7.06–6.96 (m, 2H), 6.39 (dd, J = 5.4, 2.8 Hz, 1H), 4.46 (s, 1H), 3.39 (s, 6H), 2.40 (s, 3H); 13C NMR (75 MHz, CDCl3): 185.95, 167.19, 151.58, 151.52, 139.80, 139.21, 138.96, 135.59, 134.75, 134.02, 132.59, 131.94, 130.11, 128.84, 128.37, 127.39, 126.80, 123.60, 120.51, 117.72, 113.10, 46.48, 28.85, 21.22; MS (GCMS, m/z) 523.9 [M]+; anal. calcd for C30H22ClN3O4: C, 68.77; H, 4.23; Cl, 6.77; N, 8.02; O, 12.21. Found C, 68.74; H, 4.24; Cl, 6.78; N, 8.01; O, 12.23.
5-(1-(4-Bromophenyl)-4-oxo-2-(p-tolyl)-1,4-dihydroindeno[1,2-b]pyrrol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5h). Red solid (yield 83%); mp: 294.8–295.6 °C; IR (KBr, ν/cm−1): 3431, 3057, 2960, 2914, 1694, 1679, 1603, 1505, 1456, 1376, 1288, 1117, 1087, 1015, 899, 842, 827, 766, 752, 726, 656; 1H NMR (300 MHz, CDCl3): δ (ppm), 7.53 (d, J = 8.6 Hz, 2H), 7.32 (dd, J = 5.5, 2.8 Hz, 1H), 7.25 (d, J = 8.8 Hz, 2H), 7.12 (t, J = 7.8 Hz, 4H), 7.03 (dd, J = 4.7, 3.6 Hz, 2H), 6.41 (dd, J = 5.4, 2.7 Hz, 1H), 4.51 (s, 1H), 3.38 (s, 6H), 2.33 (s, 3H); 13C NMR (75 MHz, CDCl3): 185.99, 167.18, 151.61, 150.88, 141.18, 138.88, 138.85, 136.00, 135.54, 132.63, 132.58, 130.54, 129.46, 128.68, 128.38, 125.46, 123.67, 122.78, 120.99, 117.45, 112.93, 46.49, 28.84, 21.33; MS (GCMS, m/z) 568.8 [M]+; anal. calcd for C30H22BrN3O4: C, 63.39; H, 3.90; Br, 14.06; N, 7.39; O, 11.26. Found C, 63.37; H, 3.91; Br, 14.05; N, 7.38; O, 11.29.
5-(1-(4-Chlorophenyl)-4-oxo-2-phenyl-1,4-dihydroindeno[1,2-b]pyrrol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5i). Red solid (yield 69%); mp: 272.8–273.6 °C; IR (KBr, ν/cm−1): 3435, 3059, 2960, 1693, 1680, 1605, 1505, 1445, 1378, 1291, 1262, 1192, 1093, 1017, 985, 926, 900, 867, 843, 809, 756, 727, 656; 1H NMR (300 MHz, CDCl3): δ (ppm), 7.44–7.27 (m, 8H), 7.20 (d, J = 8.6 Hz, 2H), 7.08–6.99 (m, 2H), 6.49–6.33 (m, 1H), 4.52 (s, 1H), 3.37 (s, 6H); 13C NMR (75 MHz, CDCl3): 185.98, 167.15, 151.58, 151.08, 141.06, 138.84, 135.48, 135.39, 134.85, 132.67, 130.67, 129.64, 128.85, 128.74, 128.47, 128.37, 123.72, 120.98, 117.51, 113.06, 46.46, 28.86; MS (GCMS, m/z) 510.8 [M]+; anal. calcd for C29H20ClN3O4: C, 68.31; H, 3.95; Cl, 6.95; N, 8.24; O, 12.55. Found C, 68.29; H, 3.94; Cl, 6.96; N, 8.23; O, 12.58.
5-(1,2-Bis(4-chlorophenyl)-4-oxo-1,4-dihydroindeno[1,2-b]pyrrol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5j). Dark tan solid (yield 74%); mp: 315.6–316.4 °C; IR (KBr, ν/cm−1): 3431, 3057, 2954, 2897, 1694, 1679, 1630, 1603, 1505, 1453, 1376, 1286, 1094, 1017, 984, 899, 868, 845, 836, 766, 754, 726; 1H NMR (300 MHz, CDCl3): δ (ppm), 7.40 (d, J = 8.5 Hz, 2H), 7.31 (dd, J = 16.1, 9.6 Hz, 5H), 7.20 (d, J = 8.4 Hz, 2H), 7.11–6.99 (m, 2H), 6.49–6.35 (m, 1H), 4.45 (s, 1H), 3.39 (s, 6H); MS (GCMS, m/z) 544.8 [M]+; anal. calcd for C29H19Cl2N3O4: C, 63.98; H, 3.52; Cl, 13.02; N, 7.72; O, 11.76. Found C, 63.96; H, 3.53; Cl, 13.01; N, 7.73; O, 11.77.
5-(2-(4-Chlorophenyl)-1-(4-nitrophenyl)-4-oxo-1,4-dihydroindeno[1,2-b]pyrrol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5k). Red solid (yield 86%); mp: 307.3–308.1 °C; IR (KBr, ν/cm−1): 3432, 3429, 3058, 2956, 2898, 1697, 1680, 1642, 1631, 1603, 1508, 1459, 1379, 1286, 1095, 1018, 985, 900, 868, 836, 768, 726, 755, 657; 1H NMR (300 MHz, CDCl3): δ (ppm), 8.31 (d, J = 8.9 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 7.40–7.27 (m, 5H), 7.09 (dd, J = 5.1, 3.1 Hz, 2H), 6.46 (dd, J = 5.4, 2.7 Hz, 1H), 4.46 (s, 1H), 3.40 (s, 6H); 13C NMR (75 MHz, CDCl3): 185.70, 166.80, 151.42, 150.95, 147.50, 142.00, 139.60, 138.49, 135.57, 135.00, 132.91, 131.88, 129.35, 128.95, 127.98, 126.57, 125.00, 124.10, 121.80, 117.55, 114.12, 46.31, 28.95; MS (GCMS, m/z) 555.8 [M]+; anal. calcd for C29H19ClN4O6: C, 62.77; H, 3.45; Cl, 6.39; N, 10.10; O, 17.29. Found C, 62.75; H, 3.46; Cl, 6.38; N, 10.11; O, 17.30.
5-(1-(4-Methoxyphenyl)-6,6-dimethyl-4-oxo-2-phenyl-4,5,6,7-tetrahydro-1H-indol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7a). White solid (yield 82%); mp: 254.6–255.4 °C (260.0–261.0 °C); IR (KBr, ν/cm−1): 3420, 3368, 3268, 3079, 3056, 3002, 2951, 2870, 1682, 1645, 1515, 1490, 1471, 1441, 1410, 1376, 1284, 1248, 1168, 1102, 1045, 1024, 983, 926, 847, 805, 795, 772, 754, 704, 651; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 7.29 (d, J = 6.3 Hz, 3H), 7.17 (dd, J = 9.7, 5.5 Hz, 4H), 6.95 (d, J = 8.8 Hz, 2H), 4.84 (s, 1H), 3.76 (s, 3H), 3.16 (s, 6H), 2.52 (s, 2H), 2.21 (s, 2H), 0.99 (s, 6H); 13C NMR (75 MHz, DMSO-d6): 194.10, 168.18, 159.14, 152.46, 144.30, 136.88, 130.40, 130.07, 129.69, 129.31, 128.89, 128.30, 115.81, 114.87, 112.21, 55.78, 51.39, 47.85, 36.38, 35.73, 28.82, 28.53; MS (GCMS, m/z) 500.1 [M]+; anal. calcd for C29H29N3O5: C, 69.72; H, 5.85; N, 8.41; O, 16.02. Found C, 69.73; H, 5.86; N, 8.39; O, 16.02.
5-(1-(4-Methoxyphenyl)-6,6-dimethyl-4-oxo-2-phenyl-4,5,6,7-tetrahydro-1H-indol-3-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (7b). White solid (yield 87%); mp: 292.4–293.2 °C; IR (KBr, ν/cm−1): 3226, 3107, 2957, 2869, 2844, 1760, 1719, 1691, 1645, 1515, 1493, 1471, 1445, 1405, 1368, 1300, 1252, 1205, 1168, 1114, 1034, 931, 888, 843, 807, 772, 704, 653; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 11.14 (s, 2H), 7.34–7.22 (m, 3H), 7.19–7.10 (m, 4H), 6.95 (d, J = 8.9 Hz, 2H), 4.68 (s, 1H), 3.76 (s, 3H), 2.53 (s, 2H), 2.22 (s, 2H), 1.00 (s, 6H); 13C NMR (75 MHz, DMSO-d6): 193.79, 169.72, 159.10, 151.69, 144.07, 137.06, 130.40, 130.10, 129.77, 129.30, 128.83, 128.20, 116.05, 114.86, 111.89, 55.79, 51.58, 47.57, 36.41, 35.72, 28.52; MS (GCMS, m/z) 471.9 [M]+; anal. calcd for C27H25N3O5: C, 68.78; H, 5.34; N, 8.91; O, 16.97. Found C, 68.76; H, 5.35; N, 8.90; O, 16.99.
5-(6,6-Dimethyl-4-oxo-2-phenyl-1-(p-tolyl)-4,5,6,7-tetrahydro-1H-indol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7c). White solid (yield 76%); mp: 282.6–283.4 °C; IR (KBr, ν/cm−1): 3421, 3075, 3043, 2956, 2931, 2871, 2729, 1693, 1679, 1645, 1568, 1542, 1518, 1445, 1418, 1378, 1286, 1259, 1215, 1178, 1157, 1103, 1073, 1045, 982, 929, 894, 847, 774, 756, 706, 677, 652; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 7.32–7.06 (m, 9H), 4.84 (s, 1H), 3.15 (s, 6H), 2.53 (s, 2H), 2.31 (s, 3H), 2.21 (s, 2H), 0.99 (s, 6H); 13C NMR (75 MHz, DMSO-d6): 194.02, 168.04, 152.34, 143.98, 138.08, 136.60, 134.36, 130.26, 130.18, 129.93, 128.79, 128.19, 127.72, 115.84, 112.29, 51.27, 47.71, 36.31, 35.63, 28.70, 28.39, 20.93; MS (GCMS, m/z) 484.1 [M]+; anal. calcd for C29H29N3O4: C, 72.03; H, 6.04; N, 8.69; O, 13.24. Found C, 72.01; H, 6.05; N, 8.70; O, 13.23.
5-(6,6-Dimethyl-4-oxo-2-phenyl-1-(p-tolyl)-4,5,6,7-tetrahydro-1H-indol-3-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (7d). White solid (yield 75%); mp: 324.6–325.4 °C; IR (KBr, ν/cm−1): 3414, 3220, 3103, 2957, 2871, 1759, 1720, 1694, 1645, 1515, 1493, 1405, 1367, 1287, 1257, 1204, 1111, 1049, 1033, 974, 930, 835, 803, 773, 725, 703, 653, 633; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 11.14 (s, 2H), 7.35–7.00 (m, 9H), 4.68 (s, 1H), 2.54 (s, 2H), 2.30 (s, 3H), 2.22 (s, 2H), 0.99 (s, 6H); 13C NMR (75 MHz, DMSO-d6): 193.83, 169.70, 151.68, 143.88, 138.12, 136.90, 134.56, 130.37, 130.27, 130.09, 128.85, 128.21, 127.83, 116.20, 112.09, 51.56, 49.07, 47.55, 36.46, 35.73, 28.49, 21.05; MS (GCMS, m/z) 455.9 [M]+; anal. calcd for C27H25N3O4: C, 71.19; H, 5.53; N, 9.22; O, 14.06. Found C, 71.18; H, 5.53; N, 9.21; O, 14.08.
5-(6,6-Dimethyl-4-oxo-1,2-diphenyl-4,5,6,7-tetrahydro-1H-indol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7e). White solid (yield 79%); mp: 315.0–315.8 °C; IR (KBr, ν/cm−1): 3435, 3230, 3103, 2960, 2833, 1739, 1730, 1710, 1631, 1597, 1497, 1472, 1420, 1386, 1346, 1258, 1232, 1198, 1157, 1112, 1064, 1048, 798, 771, 711, 691, 653; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 7.65–6.95 (m, 10H), 4.85 (s, 1H), 3.16 (s, 6H), 2.55 (s, 2H), 2.22 (s, 2H), 0.99 (s, 6H); 13C NMR (126 MHz, DMSO-d6): 194.07, 168.02, 152.34, 143.91, 136.89, 136.60, 130.26, 129.85, 129.71, 128.78, 128.62, 128.22, 128.01, 115.94, 112.39, 51.27, 47.71, 36.29, 35.65, 28.70, 28.38; MS (GCMS, m/z) 469.9 [M]+; anal. calcd for C28H27N3O4: C, 71.62; H, 5.80; N, 8.95; O, 13.63. Found C, 71.60; H, 5.81; N, 8.94; O, 13.65.
5-(6,6-Dimethyl-4-oxo-1,2-diphenyl-4,5,6,7-tetrahydro-1H-indol-3-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (7f). White solid (yield 71%); mp: 344.2–345.0 °C; IR (KBr, ν/cm−1): 3451, 3223, 3082, 2967, 2954, 2935, 2838, 2869, 1738, 1729, 1629, 1537, 1496, 1470, 1439, 1409, 1362, 1341, 1257, 1231, 1197, 1157, 1112, 1064, 1049, 1028, 1003, 945, 889, 819, 798, 772, 749, 711, 691, 653; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 11.14 (s, 2H), 7.55–7.02 (m, 10H), 4.69 (s, 1H), 2.56 (s, 2H), 2.23 (s, 2H), 1.00 (s, 6H); 13C NMR (75 MHz, DMSO-d6): 193.88, 169.70, 152.60, 151.71, 143.79, 137.08, 136.87, 130.36, 130.02, 129.81, 128.85, 128.12, 116.28, 112.21, 51.55, 47.57, 36.40, 35.76, 28.50; MS (GCMS, m/z) 441.9 [M]+; anal. calcd for C26H23N3O4: C, 70.73; H, 5.25; N, 9.52; O, 14.50. Found C, 70.71; H, 5.26; N, 9.51; O, 14.52.
5-(1-(4-Bromophenyl)-6,6-dimethyl-4-oxo-2-phenyl-4,5,6,7-tetrahydro-1H-indol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7g). Light pink solid (yield 84%); mp: 325.4–326.2 °C; IR (KBr, ν/cm−1): 3432, 3083, 2959, 2871, 1684, 1659, 1556, 1494, 1471, 1412, 1392, 1374, 1287, 1255, 1159, 1092, 1064, 1015, 987, 882, 855, 810, 756, 738, 724, 710, 651; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 7.62 (d, J = 8.6 Hz, 2H), 7.32 (d, J = 6.8 Hz, 3H), 7.18 (t, J = 8.2 Hz, 4H), 4.86 (s, 1H), 3.15 (s, 6H), 2.58 (s, 2H), 2.22 (s, 2H), 0.99 (s, 6H); 13C NMR (126 MHz, DMSO-d6): 194.13, 167.96, 152.31, 143.96, 136.44, 136.20, 132.67, 130.29, 130.11, 129.58, 128.95, 128.40, 121.67, 116.14, 112.65, 51.24, 47.68, 36.16, 35.67, 28.71, 28.35; MS (GCMS, m/z) 548.8 [M]+; anal. calcd for C28H26BrN3O4: C, 61.32; H, 4.78; Br, 14.57; N, 7.66; O, 11.67. Found C, 61.29; H, 4.78; Br, 14.56; N, 7.67; O, 11.70.
5-(1-(4-Bromophenyl)-6,6-dimethyl-4-oxo-2-phenyl-4,5,6,7-tetrahydro-1H-indol-3-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (7h). White solid (yield 82%); mp: 321.6–322.4 °C; IR (KBr, ν/cm−1): 3397, 3223, 3098, 2958, 2867, 1761, 1719, 1691, 1645, 1587, 1537, 1493, 1467, 1406, 1372, 1353, 1296, 1259, 1205, 1153, 1114, 1070, 1049, 1012, 970, 931, 888, 839, 810, 795, 773, 759, 725, 704, 685, 651; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 11.16 (s, 2H), 7.61 (d, J = 8.5 Hz, 2H), 7.38–7.25 (m, 3H), 7.16 (t, J = 7.6 Hz, 4H), 4.70 (s, 1H), 2.58 (s, 2H), 2.23 (s, 2H), 1.00 (s, 6H); 13C NMR (75 MHz, DMSO-d6): 193.93, 169.62, 151.68, 143.85, 136.75, 136.40, 132.76, 130.42, 130.22, 129.74, 129.00, 128.43, 121.72, 116.51, 112.47, 51.54, 49.07, 47.52, 35.78, 28.46; MS (GCMS, m/z) 520.8 [M]+; anal. calcd for C26H22BrN3O4: C, 60.01; H, 4.26; Br, 15.36; N, 8.07; O, 12.30. Found C, 59.99; H, 4.25; Br, 15.37; N, 8.06; O, 12.33.
5-(1-(4-Chlorophenyl)-6,6-dimethyl-4-oxo-2-phenyl-4,5,6,7-tetrahydro-1H-indol-3-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (7i). White solid (yield 68%); mp: 315.6–316.4 °C; IR (KBr, ν/cm−1): 3435, 3098, 2956, 2874, 1698, 1682, 1649, 1579, 1542, 1496, 1473, 1415, 1375, 1283, 1258, 1090, 1046, 1014, 984, 845, 810, 774, 758, 726, 704, 650; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 11.14 (s, 2H), 7.48 (d, J = 8.6 Hz, 2H), 7.38–7.19 (m, 5H), 7.18–7.09 (m, 2H), 4.70 (s, 1H), 2.58 (s, 2H), 2.23 (s, 2H), 1.00 (s, 6H); 13C NMR (75 MHz, DMSO-d6): 193.91, 169.62, 151.67, 143.89, 136.80, 135.98, 133.20, 130.42, 129.94, 129.82, 129.75, 128.99, 116.48, 112.43, 51.53, 47.51, 36.31, 35.77, 28.46; MS (GCMS, m/z) 476.8 [M]+; anal. calcd for C26H22ClN3O4: C, 65.62; H, 4.66; Cl, 7.45; N, 8.83; O, 13.44. Found C, 65.61; H, 4.65; Cl, 7.44; N, 8.84; O, 13.46.
5-(2-(4-Chlorophenyl)-6,6-dimethyl-4-oxo-1-phenyl-4,5,6,7-tetrahydro-1H-indol-3-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (7j). White solid (yield 83%); mp: 321.2–322.0 °C; IR (KBr, ν/cm−1): 3432, 3097, 2957, 2869, 1693, 1688, 1646, 1580, 1539, 1493, 1468, 1412, 1375, 1354, 1288, 1259, 1092, 1048, 1013, 984, 839, 812, 776, 759, 726, 704, 685, 650; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 11.17 (s, 2H), 7.42 (t, J = 7.0 Hz, 3H), 7.35 (d, J = 7.7 Hz, 2H), 7.22 (d, J = 7.6 Hz, 2H), 7.13 (d, J = 7.1 Hz, 2H), 4.73 (s, 1H), 2.56 (s, 2H), 2.23 (s, 2H), 1.00 (s, 6H); 13C NMR (75 MHz, DMSO-d6): 193.88, 169.58, 151.67, 144.06, 136.83, 135.64, 133.16, 132.11, 129.93, 128.95, 128.12, 116.36, 112.69, 51.54, 47.50, 36.39, 35.76, 28.46; MS (GCMS, m/z) 476.7 [M]+; anal. calcd for C26H22ClN3O4: C, 65.62; H, 4.66; Cl, 7.45; N, 8.83; O, 13.44. Found C, 65.61; H, 4.64; Cl, 7.45; N, 8.85; O, 13.45.
5-(1-(4-Chlorophenyl)-6,6-dimethyl-4-oxo-2-phenyl-4,5,6,7-tetrahydro-1H-indol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7k). White solid (yield 78%); mp: 310.4–311.2 °C; IR (KBr, ν/cm−1): 3422, 3099, 3080, 2956, 2931, 2869, 1698, 1682, 1648, 1567, 1544, 1496, 1473, 1415, 1375, 1283, 1258, 1171, 1157, 1113, 1090, 1075, 1026, 984, 927, 884, 844, 810, 773, 758, 726, 704, 650; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 7.49 (d, J = 8.5 Hz, 2H), 7.29 (dd, J = 15.8, 7.4 Hz, 5H), 7.16 (d, J = 5.2 Hz, 2H), 4.86 (s, 1H), 3.16 (s, 6H), 2.58 (s, 2H), 2.22 (s, 2H), 0.99 (s, 6H); 13C NMR (126 MHz, DMSO-d6): 194.12, 167.96, 152.32, 144.01, 136.49, 135.77, 133.15, 130.29, 129.83, 129.73, 129.59, 128.94, 128.39, 116.12, 112.61, 51.24, 47.69, 36.15, 35.67, 28.71, 28.36; MS (GCMS, m/z) 504.8 [M]+; anal. calcd for C28H26ClN3O4: C, 66.73; H, 5.20; Cl, 7.03; N, 8.34; O, 12.70. Found C, 66.71; H, 5.21; Cl, 7.02; N, 8.33; O, 12.73.
5-(1-(4-Chlorophenyl)-6,6-dimethyl-4-oxo-2-(thiophen-2-yl)-4,5,6,7-tetrahydro-1H-indol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7l). Light pink solid (yield 69%); mp: 301.3–302.1 °C; IR (KBr, ν/cm−1): 3435, 3081, 2958, 2870, 1682, 1651, 1548, 1496, 1472, 1416, 1374, 1284, 1255, 1156, 1091, 1061, 1016, 984, 881, 854, 806, 757, 739, 725, 709, 652; 1H NMR (500 MHz, DMSO-d6): δ (ppm), 7.56 (dd, J = 18.3, 6.8 Hz, 3H), 7.35 (d, J = 8.6 Hz, 2H), 7.10–6.94 (m, 2H), 4.97 (s, 1H), 3.16 (s, 6H), 2.55 (s, 2H), 2.22 (s, 2H), 0.99 (s, 6H); MS (GCMS, m/z) 510.8 [M]+; anal. calcd for C26H24ClN3O4S: C, 61.23; H, 4.74; Cl, 6.95; N, 8.24; O, 12.55; S, 6.29. Found C, 61.21; H, 4.75; Cl, 6.94; N, 8.23; O, 12.56; S, 6.31.
5-(1-(4-Chlorophenyl)-4,9-dioxo-2-phenyl-4,9-dihydro-1H-benzo[f]indol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (9a). Red solid (yield 61%); mp: 221.8–222.6 °C; IR (KBr, ν/cm−1): 3400, 3197, 3082, 2955, 2596, 1685, 1624, 1618, 1596, 1572, 1520, 1494, 1452, 1380, 1358, 1333, 1288, 1241, 1186, 1125, 1089, 1032, 1015, 993, 948, 923, 871, 862, 824, 816, 793, 775, 757, 722, 692, 670, 662, 657; 1H NMR (300 MHz, CDCl3): δ (ppm), 8.22 (d, J = 7.5 Hz, 1H), 8.03 (d, J = 7.4 Hz, 1H), 7.75 (dt, J = 15.0, 5.5 Hz, 5H), 7.61–7.12 (m, 6H), 4.98 (s, 1H), 3.42 (s, 6H); 13C NMR (75 MHz, CDCl3) 182.01, 173.07, 165.90, 160.61, 151.61, 151.37, 134.36, 133.72, 132.73, 132.58, 130.90, 129.26, 128.41, 128.09, 127.47, 127.13, 126.77, 112.15, 46.67, 29.21; MS (GCMS, m/z) 537.1 [M]+; anal. calcd for C30H20ClN3O5: C, 66.98; H, 3.75; Cl, 6.59; N, 7.81; O, 14.87. Found C, 66.96; H, 3.76; Cl, 6.57; N, 7.80; O, 14.91.
5-(1-(4-Methoxyphenyl)-4,9-dioxo-2-(p-tolyl)-4,9-dihydro-1H-benzo[f]indol-3-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (9b). Red solid (yield 57%); mp: 235.6–236.4 °C; IR (KBr, ν/cm−1): 3401, 3198, 2955, 2599, 2298, 1685, 1621, 1608, 1596, 1569, 1520, 1492, 1452, 1380, 1359, 1333, 1241, 1125, 1090, 1032, 1015, 948, 923, 871, 862, 824, 816, 775, 757, 722, 692, 670, 662; 1H NMR (300 MHz, CDCl3): δ (ppm), 8.62 (d, J = 6.5 Hz, 1H), 8.09 (d, J = 7.6 Hz, 1H), 7.73–7.64 (m, 2H), 7.23–7.08 (m, 6H), 6.98 (d, J = 8.6 Hz, 2H), 4.94 (s, 1H), 3.88 (s, 3H), 3.42 (s, 6H), 2.36 (s, 3H); MS (GCMS, m/z) 547.1 [M]+; anal. calcd for C32H25N3O6: C, 70.19; H, 4.60; N, 7.67; O, 17.54. Found C, 70.17; H, 4.60; N, 7.68; O, 17.55.
Typical procedure for the synthesis of pyrrolo[2,3-d]pyrimidin derivatives (11a–11j)
Amino uracil 10 (1 mmol), barbituric acid 3 (1 mmol), phenylglyoxal hydrate 4 (1 mmol), and ethanol (8 mL) were taken in a 50 mL round bottom flask. The mixture was stirred at refluxing temperature for 30 min. After completion of the reaction, the reaction mixture was cooled, formed solids were filtered and washed with cold ethanol to obtain the products 11a–j.
5-(1,3-Dimethyl-2,4-dioxo-6-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (11a). White solid (yield 88%); mp: >350.0 °C; IR (KBr, ν/cm−1): 3435, 3260, 3198, 3080, 3059, 3009, 2950, 1683, 1653, 1603, 1569, 1433, 1376, 1300, 1119, 1067, 1035, 978, 861, 793, 762, 754, 745, 708, 693, 680; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 11.94 (s, 1H), 7.77–7.23 (m, 5H), 5.17 (s, 1H), 3.51 (s, 3H), 3.17 (s, 6H), 3.13 (s, 3H); 13C NMR (75 MHz, DMSO-d6): 168.16, 159.27, 152.38, 151.06, 142.88, 139.75, 131.66, 130.84, 129.29, 128.55, 128.45, 109.17, 97.27, 47.30, 31.12, 28.91, 27.87; MS (GCMS, m/z) 409.1 [M]+; anal. calcd for C20H19N5O5: C, 58.68; H, 4.68; N, 17.11; O, 19.53. Found C, 58.66; H, 4.69; N, 17.10; O, 19.55.
5-(1,3-Dimethyl-2,4-dioxo-6-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (11b). White solid (yield 86%); mp: >350.0 °C; IR (KBr, ν/cm−1): 3395, 3223, 3088, 2948, 2885, 1708, 1689, 1652, 1603, 1567, 1509, 1497, 1448, 1410, 1365, 1322, 1276, 1256, 1231, 1190, 1125, 1068, 1048, 979, 922, 855, 818, 790, 768, 775, 743, 705, 675, 623, 605; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 11.88 (s, 1H), 11.21 (s, 2H), 7.65–7.31 (m, 5H), 5.02 (s, 1H), 3.50 (s, 3H), 3.16 (s, 3H); 13C NMR (126 MHz, DMSO-d6): 169.60, 159.02, 151.53, 150.98, 139.56, 131.77, 130.77, 129.12, 128.59, 128.43, 128.22, 126.90, 108.79, 97.36, 46.89, 30.99, 27.66; MS (GCMS, m/z) 381.1 [M]+; anal. calcd for C18H15N5O5: C, 56.69; H, 3.96; N, 18.37; O, 20.98. Found C, 56.66; H, 3.97; N, 18.36; O, 21.01.
5-(6-(4-Methoxyphenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (11c). White solid (yield 79%); mp: >350.0 °C; IR (KBr, ν/cm−1): 3420, 3368, 3268, 3079, 3056, 3002, 2952, 2870, 1683, 1645, 1516, 1441, 1413, 1376, 1302, 1285, 1170, 1105, 1057, 1028, 983, 926, 847, 795, 772, 754, 745, 708, 693, 651; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 11.86 (s, 1H), 7.50 (d, J = 8.5 Hz, 2H), 7.08 (d, J = 8.6 Hz, 2H), 5.10 (s, 1H), 3.80 (s, 3H), 3.49 (s, 3H), 3.17 (s, 6H), 3.13 (s, 3H); MS (GCMS, m/z) 439.1 [M]+; anal. calcd for C21H21N5O6: C, 57.40; H, 4.82; N, 15.94; O, 21.84. Found C, 57.38; H, 4.81; N, 15.93; O, 21.88.
5-(6-(4-Methoxyphenyl)-1,3-dimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (11d). White solid (yield 84%); mp: >350.0 °C; IR (KBr, ν/cm−1): 3391, 3226, 3108, 2956, 2872, 2845, 1718, 1707, 1691, 1651, 1604, 1569, 1514, 1492, 1451, 1409, 1366, 1302, 1254, 1208, 1191, 1169, 1114, 1037, 982, 932, 889, 843, 807, 780, 706, 673; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 11.80 (s, 1H), 11.20 (s, 2H), 7.49 (d, J = 7.9 Hz, 2H), 7.07 (d, J = 7.9 Hz, 2H), 4.95 (s, 1H), 3.80 (3, 3H), 3.49 (s, 3H), 3.16 (s, 3H); 13C NMR (75 MHz, DMSO-d6): 169.79, 159.60, 159.12, 151.64, 151.10, 139.37, 131.87, 129.95, 123.29, 114.69, 108.03, 97.31, 55.74, 46.98, 31.08, 27.77; MS (GCMS, m/z) 411.1 [M]+; anal. calcd for C19H17N5O6: C, 55.47; H, 4.17; N, 17.02; O, 23.34. Found C, 55.43; H, 4.18; N, 17.03; O, 23.36.
1,3-Dimethyl-5-(4-oxo-6-phenyl-2-thioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (11e). White solid (yield 76%); mp: >350.0 °C; IR (KBr, ν/cm−1): 3529, 3426, 3258, 3109, 3057, 2903, 1672, 1632, 1606, 1507, 1447, 1383, 1288, 1260, 1163, 1119, 1028, 990, 918, 803, 765, 699, 650; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 13.46 (s, 1H), 12.02 (s, 1H), 12.00 (s, 1H), 7.57 (d, J = 7.2 Hz, 2H), 7.53–7.39 (m, 3H), 5.15 (s, 1H), 3.16 (s, 6H); 13C NMR (75 MHz, DMSO-d6): 172.96, 168.18, 158.35, 152.30, 139.32, 132.81, 130.42, 129.20, 128.74, 108.91, 101.33, 47.06, 28.89; MS (GCMS, m/z) 397.1 [M]+; anal. calcd for C18H15N5O4S: C, 54.40; H, 3.80; N, 17.62; O, 16.11; S, 8.07. Found C, 54.39; H, 3.80; N, 17.61; O, 16.13; S, 8.07.
5-(6-(4-Bromophenyl)-4-oxo-2-thioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (11f). Light tan solid (yield 82%); mp: >350.0 °C; IR (KBr, ν/cm−1): 3384, 3243, 3105, 3034, 2886, 2343, 1671, 1602, 1505, 1451, 1428, 1382, 1290, 1262, 1184, 1163, 1119, 1006, 989, 832, 811, 758, 717, 604; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 13.49 (s, 1H), 12.07 (s, 1H), 12.02 (s, 1H), 7.69 (d, J = 8.1 Hz, 2H), 7.50 (d, J = 8.1 Hz, 2H), 5.14 (s, 1H), 3.16 (s, 6H); 13C NMR (126 MHz, DMSO-d6): 172.97, 167.92, 158.16, 152.13, 139.32, 131.98, 131.48, 130.60, 129.45, 121.89, 109.31, 101.24, 84.25, 46.86, 28.77; MS (GCMS, m/z) 474.9 [M]+; anal. calcd for C18H14BrN5O4S: C, 45.39; H, 2.96; Br, 16.78; N, 14.70; O, 13.44; S, 6.73. Found C, 45.37; H, 2.95; Br, 16.76; N, 14.71; O, 13.47; S, 6.74.
5-(6-(4-Bromophenyl)-4-oxo-2-thioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (11g). Light tan solid (yield 74%); mp: >350.0 °C; IR (KBr, ν/cm−1): 3385, 3181, 2369, 1674, 1615, 1428, 1250, 1147, 1123, 1077, 1007, 824, 780, 728, 605; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 12.03 (s, 1H), 12.00 (s, 1H), 11.81 (s, 1H), 11.27 (s, 2H), 7.68–7.65 (m, 2H), 7.48–7.45 (m, 2H), 5.01 (s, 1H); MS (GCMS, m/z) 448.9 [M]+; anal. calcd for C16H10BrN5O4S: C, 42.87; H, 2.25; Br, 17.83; N, 15.62; O, 14.28; S, 7.15. Found C, 42.84; H, 2.26; Br, 17.82; N, 15.63; O, 14.29; S, 7.16.
5-(2-Amino-4-oxo-6-phenyl-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (11h). Light olive green solid (yield 68%); mp: >350.0 °C; IR (KBr, ν/cm−1): 3474, 3382, 3109, 3043, 2914, 2870, 2788, 1679, 1633, 1556, 1432, 1380, 1327, 1317, 1288, 1267, 1250, 1179, 1157, 1124, 1108, 1076, 1041, 1022, 985, 928, 900, 874, 824, 796, 781, 753, 706, 693, 661; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 11.44 (s, 1H), 10.14 (s, 1H), 7.57 (d, J = 7.6 Hz, 2H), 7.45 (t, J = 7.5 Hz, 2H), 7.35 (t, J = 7.3 Hz, 1H), 6.28 (s, 2H), 5.10 (s, 1H), 3.16 (s, 6H); MS (GCMS, m/z) 380.1 [M]+; anal. calcd for C18H16N6O4: C, 56.84; H, 4.24; N, 22.10; O, 16.82. Found C, 56.82; H, 4.24; N, 22.10; O, 16.84.
5-(2-Amino-6-(4-bromophenyl)-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (11i). Black solid (yield 75%); mp: >350.0 °C; IR (KBr, ν/cm−1): 3427, 3382, 3181, 3042, 2916, 2871, 2369, 1678, 1617, 1514, 1429, 1326, 1311, 1290, 1255, 1179, 1147, 1123, 1098, 1078, 1002, 983, 926, 869, 825, 782, 729, 691, 657; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 11.45 (s, 1H), 11.18 (s, 2H), 10.25 (s, 1H), 7.63 (d, J = 8.3 Hz, 2H), 7.45 (d, J = 8.3 Hz, 2H), 6.27 (s, 2H), 4.97 (s, 1H); MS (GCMS, m/z) 431.9 [M]+; anal. calcd for C16H11BrN6O4: C, 44.57; H, 2.57; Br, 18.53; N, 19.49; O, 14.84. Found C, 44.55; H, 2.57; Br, 18.52; N, 19.48; O, 14.88.
5-(2-Amino-4-oxo-6-phenyl-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidine-2,4,6(1H,3H,5H)-trione (11j). Light olive green solid (yield 86%); mp: >350.0 °C; IR (KBr, ν/cm−1): 3467, 3381, 3224, 3081, 2943, 2883, 2791, 1703, 1681, 1653, 1605, 1562, 1498, 1449, 1376, 1325, 1278, 1257, 1232, 1185, 1159, 1126, 1098, 1074, 1047, 983, 924, 886, 856, 824, 792, 776, 743, 705, 683, 651; 1H NMR (300 MHz, DMSO-d6): δ (ppm), 12.18 (s, 2H), 11.52 (s, 1H), 10.44 (s, 1H), 7.45 (d, J = 7.7 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.17 (t, J = 7.2 Hz, 1H), 6.17 (s, 2H), 5.15 (s, 1H); 13C NMR (75 MHz, DMSO-d6): 170.13, 159.33, 153.27, 151.69, 151.59, 131.92, 131.24, 129.17, 127.92, 127.65, 106.90, 99.51, 47.18, 40.71, 40.44, 40.16, 39.88, 39.61, 39.33, 39.05; MS (GCMS, m/z) 352.1 [M]+; anal. calcd for C16H12N6O4: C, 54.55; H, 3.43; N, 23.85; O, 18.17. Found C, 54.53; H, 3.44; N, 23.84; O, 18.19.
Acknowledgements
We thank DST and CSIR, New Delhi for financial support to this work. YD thanks UGC, New Delhi for the award of a research fellowship. We also thank the Director, CSIR-NEIST, Jorhat, for his keen interest and constant encouragement.
Notes and references
- E. Gravel, E. Poupon and R. Hocquemiller, Org. Lett., 2005, 7, 2497 CrossRef CAS PubMed; A. S. Davis, S. G. Pyne, B. W. Skelton and A. H. White, J. Org. Chem., 2004, 69, 3139 CrossRef PubMed; A. Domling, Chem. Rev., 2006, 106, 17 CrossRef PubMed.
- J. Zhu and H. Bienayme, Multicomponent Reactions, Wiley-VCH, Weinheim, 2005 CrossRef CAS; I. Ugi, Pure Appl. Chem., 2001, 73, 187 CrossRef CAS; H. Bienayme, Chem.–Eur. J., 2000, 6, 3321 CrossRef.
- E. J. Corey and X.-M. Cheng, The Logic of Chemical Synthesis, Wiley-VCH Verlag, Weinheim, 1995 CrossRef CAS PubMed; E. Ruijter, R. Scheffelaar and R. V. A. Orru, Angew. Chem., Int. Ed., 2011, 50, 6234 CrossRef CAS PubMed.
- M. Baumann and I. R. Baxendale, Org. Lett., 2014, 16, 6076 CrossRef CAS PubMed; R. Lavilla, M. C. Bernabeu, I. Carranco and J. L. Díaz, Org. Lett., 2003, 5, 717 CrossRef PubMed; C. Simon, T. Constantieux and J. Rodriguez, Eur. J. Org. Chem., 2004, 4957 CrossRef; A. Dandia, R. Singh and S. Maheshwari, Curr. Org. Chem., 2014, 18, 2513 CrossRef; M. Nourisefat, F. Panahi and A. Khalafi-Nezhad, Org. Biomol. Chem., 2014, 12, 9419 Search PubMed; N. Kielland, F. Catti, D. Bello, N. Isambert, I. Soteras, F. J. Luque and R. Lavilla, Chem.–Eur. J., 2010, 16, 7904 CrossRef PubMed.
- J. Zhu, Eur. J. Org. Chem., 2003, 1133 CrossRef CAS; V. Nair, C. Rajesh, A. U. Vinod, S. Bindu, A. R. Sreekanth, J. S. Mathen and L. Balagopal, Acc. Chem. Res., 2003, 36, 899 CrossRef PubMed; A. Shaabani, A. Maleki, A. H. Rezayan and A. Sarvary, Mol. Diversity, 2011, 15, 41 CrossRef PubMed; I. Akritopoulou-Zanze, Curr. Opin. Chem. Biol., 2008, 12, 324 CrossRef PubMed.
- B. Eftekhari-Sis, M. Zirak and A. Akbari, Chem. Rev., 2013, 113, 2958 CrossRef CAS PubMed; X. Feng, Q. Wang, W. Lin, G.-L. Dou, Z.-B. Huang and D.-Q. Shi, Org. Lett., 2013, 15, 2542 CrossRef PubMed; B. Jiang, W. Fan, M.-Y. Sun, Q. Ye, S.-L. Wang, S.-J. Tu and G. Li, J. Org. Chem., 2014, 79, 5258 CrossRef PubMed; X.-B. Chen, Z.-C. Liu, L.-F. Yang, S.-J. Yan and J. Lin, ACS Sustainable Chem. Eng., 2014, 2, 1155 CrossRef; X.-C. Tu, W. Fan, B. Jiang, S.-L. Wang and S.-J. Tu, Tetrahedron, 2013, 69, 6100 CrossRef PubMed; J. Li, L. Liu, D. Ding, J. Sun, Y. Ji and J. Dong, Org. Lett., 2013, 15, 2884 CrossRef PubMed; X. Feng, J. Wang, W. Lin, J. Zhang, Z. Huang and D. Shi, Chin. J. Chem., 2014, 32, 889 CrossRef; X.-B. Chen, X.-Y. Wang, D.-D. Zhu, S.-J. Yan and J. Lin, Tetrahedron, 2014, 70, 1047 CrossRef PubMed; C.-X. Chena, L. Liua, D.-P. Yanga, D. Wang and Y.-J. Chen, Synlett, 2005, 2047 Search PubMed; M. Anary-Abbasinejad, K. Charkhati and H. Anaraki-Ardakani, Synlett, 2009, 1115 CrossRef PubMed.
- H. Fan, J. Peng, M. T. Hamann and J. F. Hu, Chem. Rev., 2008, 108, 264 CrossRef CAS PubMed; R. A. Jones and G. P. Bean, The chemistry of pyrroles. Academic, London, 1977 Search PubMed; J. W. Huffman, Curr. Med. Chem., 1999, 6, 705 Search PubMed.
- V. Estevez, M. Villacampa and J. C. Menendez, Chem. Soc. Rev., 2010, 39, 4402 RSC; V. Estevez, M. Villacampa and J. C. Menendez, Chem. Soc. Rev., 2014, 43, 4633 RSC; J.-Y. Liao, P.-L. Shao and Y. Zhao, J. Am. Chem. Soc., 2015, 137, 628 CrossRef CAS PubMed; X. Lin, Z. Mao, X. Dai, P. Lu and Y. Wang, Chem. Commun., 2011, 47, 6620 RSC; X. Wang, X. P. Xu, S. Y. Wang, W. Zhou and S. J. Ji, Org. Lett., 2013, 15, 4246 CrossRef PubMed; H. Wang, X. Liu, X. Feng, Z. Huang and D. Shi, Green Chem., 2013, 15, 3307 RSC; N. Sharma, Z. Li, U. K. Sharma and E. V. V. D. Eycken, Org. Lett., 2014, 16, 3884 CrossRef PubMed; Y. Lian, T. Huber, K. D. Hesp, R. G. Bergman and J. A. Ellman, Angew. Chem., Int. Ed., 2013, 52, 629 CrossRef PubMed; Q.-Q. Shi, L.-P. Fu, Y. Shi, H.-Q. Ding, J.-H. Luo, B. Jiang and S.-J. Tu, Tetrahedron Lett., 2013, 54, 3176 CrossRef PubMed; S. Karamthulla, S. Pal, M. N. Khan and L. H. Choudhury, Synlett, 2014, 25, 1926 CrossRef PubMed.
- B. Jiang, Y. Li, M.-S. Tu, S.-L. Wang, S.-J. Tu and G. Li, J. Org. Chem., 2012, 77, 7497 CrossRef CAS PubMed; G. R. Humphrey and J. T. Kuethe, Chem. Rev., 2006, 106, 2875 CrossRef PubMed; L.-P. Fu, Q.-Q. Shi, Y. Shi, B. Jiang and S.-J. Tu, ACS Comb. Sci., 2013, 15, 135 CrossRef PubMed; S. Kotha and A. K. Chinnam, Synthesis, 2014, 46, 301 CrossRef PubMed; K. Sapeta, T. P. Lebold and M. A. Kerr, Synlett, 2011, 1495 Search PubMed; H. Wang and D. Shi, ACS Comb. Sci., 2013, 15, 261 CrossRef PubMed; S. Maity and A. Pramanik, Synthesis, 2013, 45, 2853 CrossRef PubMed.
- V. Dhayalan, J. A. Clement, R. Jagan and A. K. Mohanakrishnan, Eur. J. Org. Chem., 2009, 531 CrossRef CAS; N. Ramkumar and R. Nagarajan, Tetrahedron Lett., 2014, 55, 1104 CrossRef PubMed; P. Bernal, A. Benavides, R. Bautista and J. Tamariz, Synthesis, 2007, 1943 Search PubMed.
- S. Paul and A. R. Das, Catal. Sci. Technol., 2012, 2, 1130 Search PubMed; J. Quiroga, P. A. Acosta, S. Cruz, R. Abonía, B. Insuasty, M. Nogueras and J. Cobo, Tetrahedron Lett., 2010, 51, 5443 CrossRef CAS PubMed; V. Prieur, J. Rubio-Martínez, M. Font-Bardia, G. Guillaumet and M. D. Pujol, Eur. J. Org. Chem., 2014, 1514 CrossRef; K. C. Majumdar, A. Biswas and P. P. Mukhopadhyay, Synthesis, 2005, 1164 CrossRef PubMed; L. Zhao, K. Tao, H. Li and J. Zhang, Tetrahedron, 2011, 67, 2803 CrossRef PubMed.
- A. Alizadeh, A. Zarei and A. Rezvanian, Synthesis, 2011, 497 CrossRef CAS PubMed; Y. Luo and J. Wu, Org. Lett., 2012, 14, 1592 CrossRef PubMed; S. Muthusaravanan, C. Sasikumar, B. D. Bala and S. Perumal, Green Chem., 2014, 16, 1297 RSC.
- Y.-L. Wua, C.-P. Chuanga and P.-Y. Lin, Tetrahedron, 2001, 57, 5543 CrossRef CAS; H.-Y. Hu, Y. Liu, M. Ye and J.-H. Xu, Synlett, 2006, 1913 Search PubMed; J. C. Barcia, J. M. Otero, J. C. Estevez and R. J. Estevez, Synlett, 2007, 1399 Search PubMed.
- S. R. Walker, E. J. Carter, B. C. Huff and J. C. Morris, Chem. Rev., 2009, 109, 3080 CrossRef CAS PubMed; S. Wang, G. Wood, C. Meades, G. Griffiths, C. Midgley, I. McNae, C. McInnes, S. Anderson, W. Jackson, M. Mezna, R. Yuill, M. Walkinshaw and P. M. Fischer, Bioorg. Med. Chem. Lett., 2004, 14, 4237 CrossRef PubMed; M. Sisa, D. Pla, M. Altuna, A. Francesch, C. Cuevas, F. Albericio and M. Alvarez, J. Med. Chem., 2009, 52, 6217 CrossRef PubMed; F. Giraud, G. Alves, E. Debiton, L. Nauton, V. Théry, E. Durieu, Y. Ferandin, O. Lozach, L. Meijer, F. Anizon, E. Pereira and P. Moreau, J. Med. Chem., 2011, 54, 4474 CrossRef PubMed.
- K. Shanab, E. Schirmer, H. Knafl, E. Wulz, W. Holzer, H. Spreitzer, P. Schmidt, B. Aicher, G. Muller and E. Gunther, Bioorg. Med. Chem. Lett., 2010, 20, 3950 CrossRef CAS PubMed; L. Hu, Z. Li, L. Li, J. Qu, Y.-H. Ling, J. Jiang and D. W. Boykin, J. Med. Chem., 2006, 49, 6273 CrossRef PubMed; J. F. Dropinski, T. Akiyama, M. Einstein, B. Habulihaz, T. Doebber, J. P. Berger, P. T. Meinke and G. Q. Shi, Bioorg. Med. Chem. Lett., 2005, 15, 5035 CrossRef PubMed.
- D. Bhuyan, R. Sarma, Y. Dommaraju and D. Prajapati, Green Chem., 2014, 16, 1158 RSC; M. M. Sarmah, D. Bhuyan and D. Prajapati, Synlett, 2013, 24, 1667 CrossRef CAS PubMed; Y. Dommaraju and D. Prajapati, Mol. Diversity, 2015, 19, 173 CrossRef PubMed; M. M. Sarmah, D. Prajapati and W. Hu, Synlett, 2013, 24, 471 CrossRef PubMed; R. Sarma, M. M. Sarmah and D. Prajapati, J. Org. Chem., 2012, 77, 2018 CrossRef PubMed; D. Bhuyan, M. M. Sarmah, Y. Dommaraju and D. Prajapati, Tetrahedron Lett., 2014, 55, 5133 CrossRef PubMed; R. Sarma, K. J. Borah, Y. Dommaraju and D. Prajapati, Mol. Diversity, 2011, 15, 697 CrossRef PubMed.
- P. Simunek, A. Lycka and V. Machacek, Eur. J. Org. Chem., 2002, 2764 CrossRef CAS.
- L. L. Gozalishvilia, T. V. Beryozkinaa, I. V. Omelchenkob, R. I. Zubatyukb, O. V. Shishkinb and N. N. Kolos, Tetrahedron, 2008, 64, 8759 CrossRef PubMed.
- H. A. Riley and A. R. Gray, Org. Synth., 1935, 15, 67 CrossRef.
Footnote |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c5ra00796h |
|
This journal is © The Royal Society of Chemistry 2015 |
Click here to see how this site uses Cookies. View our privacy policy here.